Profile
A healthy individual can mount an immune response to pathogens and tumors while avoiding an autoimmune attack on normal tissues. Our lab studies how signal transduction pathways regulate lymphocyte development, activation and tolerance.
We are exploring:
- How deregulation of signaling pathways in developing lymphocytes leads to the development of hematological cancers.
- We are part of a multidisciplinary consortium who’s goals are to use a precision medicine-based approach to:
- develop tumor-specific delivery of our novel anti-leukemia/lymphoma drugs.
- utilize a high throughput neoantigen discovery platform to improve immunotherapy outcomes for multiple types of cancer.
- How lymphocyte receptors signal the programs that distinguish immune protection from immune pathology for infectious disease.
Academic Information
Associate Professor
Molecular Pathogenesis and Therapeutics Graduate Program
NextGen Precision Health Investigator
Office
1030 Hitt St
Room 2010 NextGen Precision Health Institute
Columbia, MO 65211
United States
P. 573-884-1659
Research Interests
- T and B cell biology
- Tumor immunotherapy
- Leukemia
- Lymphoma
- Autoimmunity
- Immune Response to Pathogens
- Signal Transduction
- Biochemistry
- Immunology
- Drug Development
Areas of Expertise
- T and B cell development and activation
- T cell engineering
- Lymphocyte signaling, oncology and cell biology
Education & Training
Post-Graduate School
2002, PhD, University of Minnesota
